Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
Yuan Zong, Jiajia Yuan, Zhi Peng, Ming Lu, Xicheng Wang, Lin Shen, Jun Zhou
Topics & Concepts
MedicineGemcitabineInternal medicineClinical endpointRashGastroenterologyProgression-free survivalChemotherapyOncologyHematologyPaclitaxelRandomized controlled trialSurgeryPancreatic and Hepatic Oncology ResearchNeuroendocrine Tumor Research AdvancesCholangiocarcinoma and Gallbladder Cancer Studies